drugset / Trial / NCT00593450

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

NCT00593450

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule. A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.

Timeline

Start
2008-02
Primary completion
2010-12
Completion
2015-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal